BEAM
Beam Therapeutics Inc

6,430
Mkt Cap
$2.92B
Volume
2.89M
52W High
$36.44
52W Low
$13.53
PE Ratio
-28.25
BEAM Fundamentals
Price
$27.22
Prev Close
$28.69
Open
$27.17
50D MA
$28.77
Beta
1.84
Avg. Volume
1.66M
EPS (Annual)
-$0.8088
P/B
2.36
Rev/Employee
$273,469.67
$1,650.58
Loading...
Loading...
News
all
press releases
Vanguard Group Inc. Sells 455,440 Shares of Beam Therapeutics Inc. $BEAM
Vanguard Group Inc. reduced its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 4.7% in the third quarter, according to its most recent filing with the Securities...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Beam Therapeutics (NASDAQ:BEAM) Raised to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Beam Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·4d ago
News Placeholder
Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.3% - Time to Sell?
Beam Therapeutics (NASDAQ:BEAM) Shares Down 6.3% - Here's Why...
MarketBeat·6d ago
News Placeholder
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.
Zacks·6d ago
News Placeholder
Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $26.00
Royal Bank Of Canada raised their price target on Beam Therapeutics from $22.00 to $26.00 and gave the stock a "sector perform" rating in a report on Wednesday...
MarketBeat·6d ago
News Placeholder
Beam Therapeutics (NASDAQ:BEAM) Stock Price Expected to Rise, Wedbush Analyst Says
Wedbush boosted their target price on shares of Beam Therapeutics from $57.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday...
MarketBeat·6d ago
News Placeholder
Beam Therapeutics Q4 Earnings Call Highlights
Beam Therapeutics (NASDAQ:BEAM) outlined a new liver-targeted development program for phenylketonuria (PKU) and announced a large, non-dilutive financing tied to its sickle cell disease launch plans...
MarketBeat·7d ago
News Placeholder
Beam Therapeutics (NASDAQ:BEAM) Shares Gap Up on Strong Earnings
Beam Therapeutics (NASDAQ:BEAM) Shares Gap Up on Earnings Beat...
MarketBeat·7d ago
News Placeholder
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +91.15% and +676.25%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Vestmark Advisory Solutions Inc. Sells 156,703 Shares of Beam Therapeutics Inc. $BEAM
Vestmark Advisory Solutions Inc. lessened its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 48.5% during the third quarter, according to the company in its most recent...
MarketBeat·7d ago
<
1
2
...
>

Latest BEAM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.